Sarcoma
Welcome,         Profile    Billing    Logout  
 504 Companies   302 Products   302 Products   167 Mechanisms of Action   1357 Trials   122306 News 


«12...7891011121314151617...15251526»
  • ||||||||||  Biomarker, Journal:  Prognostic factors in uterine adenosarcoma: subanalysis of the SARCUT study. (Pubmed Central) -  Jun 5, 2024   
    The most significant prognostic factors in uterine adenosarcoma were age and FIGO stage and, indirectly, tumour size at diagnosis. The use of secondary surgery and/or radiotherapy could help in prolonging the disease-free status of the patients.
  • ||||||||||  Journal:  Sinonasal chondrosarcoma in a llama. (Pubmed Central) -  Jun 5, 2024   
    Collectively, postmortem dissection, cytology, and histopathology of the primary mass supported a diagnosis of sinonasal chondrosarcoma. To our knowledge, this entity had not been reported previously in this species and should be considered a differential for facial deformities in New World camelids.
  • ||||||||||  Trial completion date, Trial primary completion date:  Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study (clinicaltrials.gov) -  Jun 5, 2024   
    P4,  N=20, Recruiting, 
    To our knowledge, this entity had not been reported previously in this species and should be considered a differential for facial deformities in New World camelids. Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
  • ||||||||||  Journal:  POLE-mutated Endometrial "Carcinosarcoma". (Pubmed Central) -  Jun 4, 2024   
    On subsequent molecular testing pathogenic POLE mutations were detected and a descriptive diagnosis of endometrial endometrioid carcinomas, low-grade with a homologous sarcoma component was rendered. This challenges the existence of POLE-mutated "carcinosarcoma."
  • ||||||||||  imatinib / Generic mfg.
    Journal, Stroma:  Management of gastrointestinal stromal tumors (Pubmed Central) -  Jun 4, 2024   
    The development of tyrosine kinase inhibitors targeting KIT and PDGFRA has revolutionized the prognosis of metastatic GIST, by increasing the median overall survival: from less than 18 months to more than 70 months within 20 years. Similary to other histological subtypes, the diagnostic and therapeutic management of GIST must be referred to sarcoma reference centers.
  • ||||||||||  Journal:  Synovial myxosarcoma in the scapulohumeral joint of a dog: a case report. (Pubmed Central) -  Jun 4, 2024   
    These findings are consistent with low-grade synovial myxosarcoma, a not well described synovial neoplasm that can mimic other commonly seen joint tumors or even septic arthritis on radiographs. The purpose of this case report is to describe the first reported synovial myxosarcoma affecting the scapulohumeral joint of a small dog.
  • ||||||||||  Observational data, Journal:  Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations. (Pubmed Central) -  Jun 4, 2024   
    P=N/A
    In addition, the presence of TERT promoter mutation in 2 of 3 RMS and lack of FOXO1 and other gene fusions in all 4 RMSs suggest a mucosal (urothelial) origin, probably representing extensive monomorphic rhabdomyoblastic transdifferentiation in SCNEC. Although the female's innate and adaptive immunity has been observed to be more active than the male's, women in the subgroup of clear cell histology, sarcomatoid differentiation, and those under 50
  • ||||||||||  Review, Journal:  A bibliometric analysis of interstitial cells of Cajal research. (Pubmed Central) -  Jun 4, 2024   
    However, further research and collaboration on a global scale are still needed. Our analysis is particularly valuable to researchers in gastroenterology, oncology, and cell biology, providing insights that can guide future research directions.
  • ||||||||||  pulrodemstat (CC-90011) / BMS, iadademstat (ORY-1001) / Oryzon, seclidemstat (SP2577) / Salarius
    Journal, Epigenetic controller:  Anticancer Drugs of Lysine Specific Histone Demethylase-1 (LSD1) Display Variable Inhibition on Nucleosome Substrates. (Pubmed Central) -  Jun 4, 2024   
    These data show that SP-2577 is not an LSD1 enzyme inhibitor, although the drug may function independent of demethylation due to its cytotoxic selectivity in TC-32 cells. Taken together, this work highlights the pitfalls of using coupled assays to ascribe a drug's mode of action, emphasizes the use of physiologically relevant substrates in epigenetic drug targeting strategies, and provides insight into the development of substrate-selective inhibitors of LSD1.
  • ||||||||||  Journal:  PSMA-Avid Desmoid Tumor of the Abdominal Wall on 18F-Piflufolastat PET/CT. (Pubmed Central) -  Jun 4, 2024   
    We outline a case report of a 62-year-old man with history of prostate cancer treated with surgery, salvage radiation, and hormonal therapy presenting with rising PSA levels. There was incidental detection of a PSMA-avid subcutaneous abdominal wall mass on PSMA PET/CT study, which was consistent with desmoid fibromatosis on an ultrasound-guided biopsy.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Enrollment closed:  EREMISS: Phase II Study of Regorafenib as Maintenance Therapy (clinicaltrials.gov) -  Jun 4, 2024   
    P2,  N=127, Active, not recruiting, 
    Therefore, TFP-Cu could be a potential candidate for treating osteosarcoma and bioactive drug carrier for further cancer-related applications. Suspended --> Active, not recruiting
  • ||||||||||  Journal:  Portal leiomyosarcoma: An extremely rare location! (Pubmed Central) -  Jun 3, 2024   
    To eliminate a duodenal origin of the mass we performed an upper digestive endoscopy which came back without any abnormality. An ultrasound-guided trans parietal biopsy of a secondary hepatic lesion was done and the pathological result of which speaks of a secondary hepatic lesion of a leiomyosarcoma.
  • ||||||||||  Journal:  Resection to restoration: Assessing the synergy of polypropylene mesh (Marlex (Pubmed Central) -  Jun 3, 2024   
    These results are especially promising in the setting of small-volume disease and differentiating tumor from inflammatory uptake. On an average, 2 ribs (range: 1-5) were removed during the surgeries, and the chest-wall defects ranged from 20 to 150
  • ||||||||||  Preclinical, Journal:  Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models. (Pubmed Central) -  Jun 3, 2024   
    We discuss the establishment of early-passage cultures from GEM MPNSTs, how to characterize these cultures using immunocytochemistry, and how to verify their tumorigenicity by establishing allografts. Collectively, these techniques characterize the pathology of PNs and MPNSTs that arise in GEM models and critically compare the pathology of these murine tumors to their human counterparts.
  • ||||||||||  Journal:  Synovial myxoma or myxosarcoma? Lymph node metastasis in 2 dogs. (Pubmed Central) -  Jun 3, 2024   
    We suggest the term "synovial myxosarcoma," considering that histologic features of the primary tumor do not predict biologic behavior. Our case series highlights the importance of lymph node sampling in suspected synovial myxosarcoma cases as well as thorough histologic examination, emphasizing careful evaluation for lymphovascular invasion.
  • ||||||||||  Journal, Surgery:  Changes in walking function and neural control following pelvic cancer surgery with reconstruction. (Pubmed Central) -  Jun 3, 2024   
    Furthermore, the participant's post-surgery muscle activations were fitted accurately using his pre-surgery synergy activations but fitted poorly using his pre-surgery synergy vectors. These results provide valuable information about which aspects of post-surgery walking function could potentially be improved through modifications to surgical decisions, custom prosthesis design, or rehabilitation protocol, as well as how computational simulations could be formulated to predict post-surgery walking function reliably given a patient's pre-surgery walking data and the planned surgical decisions and custom prosthesis design.
  • ||||||||||  Review, Journal:  MicroRNAs and angiosarcoma: are there promising reports? (Pubmed Central) -  Jun 3, 2024   
    Moving forward, it is imperative for studies to thoroughly scrutinize the advantages and disadvantages of miRNAs compared to current diagnostic and prognostic approaches in angiosarcoma and other cardiovascular tumors. Closing these knowledge gaps will be crucial for harnessing the full potential of miRNAs in the realm of angiosarcoma and cardiovascular tumor research.
  • ||||||||||  Preclinical, Journal:  Establishment of humanised xenograft models as in vivo study for lung metastasis of osteosarcoma. (Pubmed Central) -  Jun 3, 2024   
    In conclusion, this study has successfully established a lung metastatic OS mouse model that could be useful for biological studies of OS. These findings imply that this model is essential for safety and efficacy before clinical trials, accelerate the translation from basic research to therapeutic applications.
  • ||||||||||  Journal:  BiZact-Assisted Endoscopic Resection of a Sinonasal Tumor. (Pubmed Central) -  Jun 3, 2024   
    The BiZact device allows efficient sinonasal surgery because it has the unique advantage of one-step sealing and cutting. BiZact-assisted endoscopic sinonasal tumor surgery is a beneficial and safe procedure that reduces blood loss during surgery, shortens the operative time, and minimizes postoperative complications.
  • ||||||||||  Journal:  Disaggregation-Activated pan-COX Imaging Agents for Human Soft Tissue Sarcoma. (Pubmed Central) -  Jun 3, 2024   
    CNS embryonal tumors with EWSR1-PLAGL1 rearrangements acquire or include a population of cells with SMARCB1 alterations that are the component that predominate at relapse, suggesting treatment aimed at this disease component at diagnosis should be considered. More importantly, the